Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure

Jay N. Cohn, Donald G. Archibald, Susan Ziesche, Joseph A. Franciosa, W. Eugene Harston, Felix E. Tristani, W. Bruce Dunkman, William Jacobs, Gary S. Francis, Kathleen H. Flohr, Steven Goldman, Frederick R. Cobb, Pravin M. Shah, Robert Saunders, Ross D. Fletcher, Henry S. Loeb, Vincent C. Hughes, Bonnie Baker

Research output: Contribution to journalArticle

1881 Citations (Scopus)

Abstract

To evaluate the effects of vasodilator therapy on mortality among patients with chronic congestive heart failure, we randomly assigned 642 men with impaired cardiac function and reduced exercise tolerance who were taking digoxin and a diuretic to receive additional double-blind treatment with placebo, prazosin (20 mg per day), or the combination of hydralazine (300 mg per day) and isosorbide dinitrate (160 mg per day). Follow-up averaged 2.3 years (range, 6 months to 5.7 years). Mortality over the entire follow-up period was lower in the group that received hydralazine and isosorbide dinitrate than in the placebo group. This difference was of borderline statistical significance. For mortality by two years, a major end point specified in the protocol, the risk reduction among patients treated with both hydralazine and isosorbide dinitrate was 34 percent (P<0.028). The cumulative mortality rates at two years were 25.6 percent in the hydralazine–isosorbide dinitrate group and 34.3 percent in the placebo group; at three years, the mortality rate was 36.2 percent versus 46.9 percent. The mortality-risk reduction in the group treated with hydralazine and isosorbide dinitrate was 36 percent by three years. The mortality in the prazosin group was similar to that in the placebo group. Left ventricular ejection fraction (measured sequentially) rose significantly at eight weeks and at one year in the group treated with hydralazine and isosorbide dinitrate but not in the placebo or prazosin groups. Our data suggest that the addition of hydralazine and isosorbide dinitrate to the therapeutic regimen of digoxin and diuretics in patients with chronic congestive heart failure can have a favorable effect on left ventricular function and mortality. (N Engl J Med 1986; 314:1547–52.), THE demonstration of a favorable hemodynamic response to vasodilator drugs in patients with congestive heart failure has led to the wide use of these agents to supplement digitalis and diuretics in the treatment of symptomatic patients.

Original languageEnglish (US)
Pages (from-to)1547-1552
Number of pages6
JournalNew England Journal of Medicine
Volume314
Issue number24
DOIs
StatePublished - Jun 12 1986
Externally publishedYes

Fingerprint

Isosorbide Dinitrate
Vasodilator Agents
Hydralazine
Heart Failure
Mortality
Placebos
Prazosin
Diuretics
Digoxin
Risk Reduction Behavior
Therapeutics
Exercise Tolerance
Digitalis
Left Ventricular Function
Stroke Volume
Hemodynamics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., ... Baker, B. (1986). Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. New England Journal of Medicine, 314(24), 1547-1552. https://doi.org/10.1056/NEJM198606123142404

Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. / Cohn, Jay N.; Archibald, Donald G.; Ziesche, Susan; Franciosa, Joseph A.; Harston, W. Eugene; Tristani, Felix E.; Dunkman, W. Bruce; Jacobs, William; Francis, Gary S.; Flohr, Kathleen H.; Goldman, Steven; Cobb, Frederick R.; Shah, Pravin M.; Saunders, Robert; Fletcher, Ross D.; Loeb, Henry S.; Hughes, Vincent C.; Baker, Bonnie.

In: New England Journal of Medicine, Vol. 314, No. 24, 12.06.1986, p. 1547-1552.

Research output: Contribution to journalArticle

Cohn, JN, Archibald, DG, Ziesche, S, Franciosa, JA, Harston, WE, Tristani, FE, Dunkman, WB, Jacobs, W, Francis, GS, Flohr, KH, Goldman, S, Cobb, FR, Shah, PM, Saunders, R, Fletcher, RD, Loeb, HS, Hughes, VC & Baker, B 1986, 'Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure', New England Journal of Medicine, vol. 314, no. 24, pp. 1547-1552. https://doi.org/10.1056/NEJM198606123142404
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. New England Journal of Medicine. 1986 Jun 12;314(24):1547-1552. https://doi.org/10.1056/NEJM198606123142404
Cohn, Jay N. ; Archibald, Donald G. ; Ziesche, Susan ; Franciosa, Joseph A. ; Harston, W. Eugene ; Tristani, Felix E. ; Dunkman, W. Bruce ; Jacobs, William ; Francis, Gary S. ; Flohr, Kathleen H. ; Goldman, Steven ; Cobb, Frederick R. ; Shah, Pravin M. ; Saunders, Robert ; Fletcher, Ross D. ; Loeb, Henry S. ; Hughes, Vincent C. ; Baker, Bonnie. / Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. In: New England Journal of Medicine. 1986 ; Vol. 314, No. 24. pp. 1547-1552.
@article{24759331f9224f7396a455d7a9d0b0fa,
title = "Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure",
abstract = "To evaluate the effects of vasodilator therapy on mortality among patients with chronic congestive heart failure, we randomly assigned 642 men with impaired cardiac function and reduced exercise tolerance who were taking digoxin and a diuretic to receive additional double-blind treatment with placebo, prazosin (20 mg per day), or the combination of hydralazine (300 mg per day) and isosorbide dinitrate (160 mg per day). Follow-up averaged 2.3 years (range, 6 months to 5.7 years). Mortality over the entire follow-up period was lower in the group that received hydralazine and isosorbide dinitrate than in the placebo group. This difference was of borderline statistical significance. For mortality by two years, a major end point specified in the protocol, the risk reduction among patients treated with both hydralazine and isosorbide dinitrate was 34 percent (P<0.028). The cumulative mortality rates at two years were 25.6 percent in the hydralazine–isosorbide dinitrate group and 34.3 percent in the placebo group; at three years, the mortality rate was 36.2 percent versus 46.9 percent. The mortality-risk reduction in the group treated with hydralazine and isosorbide dinitrate was 36 percent by three years. The mortality in the prazosin group was similar to that in the placebo group. Left ventricular ejection fraction (measured sequentially) rose significantly at eight weeks and at one year in the group treated with hydralazine and isosorbide dinitrate but not in the placebo or prazosin groups. Our data suggest that the addition of hydralazine and isosorbide dinitrate to the therapeutic regimen of digoxin and diuretics in patients with chronic congestive heart failure can have a favorable effect on left ventricular function and mortality. (N Engl J Med 1986; 314:1547–52.), THE demonstration of a favorable hemodynamic response to vasodilator drugs in patients with congestive heart failure has led to the wide use of these agents to supplement digitalis and diuretics in the treatment of symptomatic patients.",
author = "Cohn, {Jay N.} and Archibald, {Donald G.} and Susan Ziesche and Franciosa, {Joseph A.} and Harston, {W. Eugene} and Tristani, {Felix E.} and Dunkman, {W. Bruce} and William Jacobs and Francis, {Gary S.} and Flohr, {Kathleen H.} and Steven Goldman and Cobb, {Frederick R.} and Shah, {Pravin M.} and Robert Saunders and Fletcher, {Ross D.} and Loeb, {Henry S.} and Hughes, {Vincent C.} and Bonnie Baker",
year = "1986",
month = "6",
day = "12",
doi = "10.1056/NEJM198606123142404",
language = "English (US)",
volume = "314",
pages = "1547--1552",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "24",

}

TY - JOUR

T1 - Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure

AU - Cohn, Jay N.

AU - Archibald, Donald G.

AU - Ziesche, Susan

AU - Franciosa, Joseph A.

AU - Harston, W. Eugene

AU - Tristani, Felix E.

AU - Dunkman, W. Bruce

AU - Jacobs, William

AU - Francis, Gary S.

AU - Flohr, Kathleen H.

AU - Goldman, Steven

AU - Cobb, Frederick R.

AU - Shah, Pravin M.

AU - Saunders, Robert

AU - Fletcher, Ross D.

AU - Loeb, Henry S.

AU - Hughes, Vincent C.

AU - Baker, Bonnie

PY - 1986/6/12

Y1 - 1986/6/12

N2 - To evaluate the effects of vasodilator therapy on mortality among patients with chronic congestive heart failure, we randomly assigned 642 men with impaired cardiac function and reduced exercise tolerance who were taking digoxin and a diuretic to receive additional double-blind treatment with placebo, prazosin (20 mg per day), or the combination of hydralazine (300 mg per day) and isosorbide dinitrate (160 mg per day). Follow-up averaged 2.3 years (range, 6 months to 5.7 years). Mortality over the entire follow-up period was lower in the group that received hydralazine and isosorbide dinitrate than in the placebo group. This difference was of borderline statistical significance. For mortality by two years, a major end point specified in the protocol, the risk reduction among patients treated with both hydralazine and isosorbide dinitrate was 34 percent (P<0.028). The cumulative mortality rates at two years were 25.6 percent in the hydralazine–isosorbide dinitrate group and 34.3 percent in the placebo group; at three years, the mortality rate was 36.2 percent versus 46.9 percent. The mortality-risk reduction in the group treated with hydralazine and isosorbide dinitrate was 36 percent by three years. The mortality in the prazosin group was similar to that in the placebo group. Left ventricular ejection fraction (measured sequentially) rose significantly at eight weeks and at one year in the group treated with hydralazine and isosorbide dinitrate but not in the placebo or prazosin groups. Our data suggest that the addition of hydralazine and isosorbide dinitrate to the therapeutic regimen of digoxin and diuretics in patients with chronic congestive heart failure can have a favorable effect on left ventricular function and mortality. (N Engl J Med 1986; 314:1547–52.), THE demonstration of a favorable hemodynamic response to vasodilator drugs in patients with congestive heart failure has led to the wide use of these agents to supplement digitalis and diuretics in the treatment of symptomatic patients.

AB - To evaluate the effects of vasodilator therapy on mortality among patients with chronic congestive heart failure, we randomly assigned 642 men with impaired cardiac function and reduced exercise tolerance who were taking digoxin and a diuretic to receive additional double-blind treatment with placebo, prazosin (20 mg per day), or the combination of hydralazine (300 mg per day) and isosorbide dinitrate (160 mg per day). Follow-up averaged 2.3 years (range, 6 months to 5.7 years). Mortality over the entire follow-up period was lower in the group that received hydralazine and isosorbide dinitrate than in the placebo group. This difference was of borderline statistical significance. For mortality by two years, a major end point specified in the protocol, the risk reduction among patients treated with both hydralazine and isosorbide dinitrate was 34 percent (P<0.028). The cumulative mortality rates at two years were 25.6 percent in the hydralazine–isosorbide dinitrate group and 34.3 percent in the placebo group; at three years, the mortality rate was 36.2 percent versus 46.9 percent. The mortality-risk reduction in the group treated with hydralazine and isosorbide dinitrate was 36 percent by three years. The mortality in the prazosin group was similar to that in the placebo group. Left ventricular ejection fraction (measured sequentially) rose significantly at eight weeks and at one year in the group treated with hydralazine and isosorbide dinitrate but not in the placebo or prazosin groups. Our data suggest that the addition of hydralazine and isosorbide dinitrate to the therapeutic regimen of digoxin and diuretics in patients with chronic congestive heart failure can have a favorable effect on left ventricular function and mortality. (N Engl J Med 1986; 314:1547–52.), THE demonstration of a favorable hemodynamic response to vasodilator drugs in patients with congestive heart failure has led to the wide use of these agents to supplement digitalis and diuretics in the treatment of symptomatic patients.

UR - http://www.scopus.com/inward/record.url?scp=0022623381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022623381&partnerID=8YFLogxK

U2 - 10.1056/NEJM198606123142404

DO - 10.1056/NEJM198606123142404

M3 - Article

VL - 314

SP - 1547

EP - 1552

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 24

ER -